BioSpace News Archive

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a business update and announced financial results for the first quarter ended March 31, 2020 .

Invivoscribe is pleased to announce that their LeukoStrat® CDx FLT3 Mutation Assay was submitted to regulatory authorities in China in April in support of the Astellas New Drug Application submission of XOSPATA® for treatment of adult patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

Nature Biotechnology Publishes Comprehensive Description and Validation of the GeoMx Digital Spatial Profiler Using both nCounter & NGS Read Outs

POINT Biopharma Inc. is pleased to announce the selection of PSI CRO to manage its phase 3 clinical study of PNT2002, a 177Lu-PSMA radiotherapeutic for the treatment of metastatic castrate-resistant prostate cancer.

Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, for breast cancer treatment, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic.

Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Ph.D., Chairman, President and Chief Executive Officer of Landos, will present at the following upcoming investor conferences. Presentation Details: Event: UBS Virtual Global Healthcare Conference Date: Tuesday, May 19, 2020 Time: 1:

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced that the company is scheduled to present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020 at 3:40 p.m. ET.

Remain on track to resubmit FUROSCIX® NDA with the FDA by mid-year 2020 Strong balance sheet with over $75M in cash Projected annual loss for 2020 narrows to $36-40M BURLINGTON, Mass.--( BUSINESS WIRE )-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs,

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the 2020 UBS Virtual Global Healthcare Conference on May 19, 2020 at 3:00 p.m. ET. A live webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com . A replay of the webcast will be available on Concert’s website for two weeks following the presen

Enhanced dystrophin expression in multiple muscle tissues and sustained functional benefit in DMD disease model following single low dose